Augurex Life Sciences Corp.: federal grants and contributions: 6 agreements; $5.6M value; 2 departments; 3 programs.
Assay record ASY-CA-1K2UK8413Z · Cite as: Assay Systems, “Augurex Life Sciences Corp.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/augurex-life-sciences-corp/
Commercialize autoantibody test for early detection and monitoring of autoimmune diseases
Support sales and marketing of autoimmune disease test for the point-of-care market
The main objective of this project is to identify a lead biological candidate for the treatment of Rheumatoid Arthritis (RA).
The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a specific target market, particularly where activities are targeting departmental priority markets and sectors.
The 14-3-3 eta JOINTstat® test can be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augurex plans to commercialize 14-3-3 eta tests and reagents in Germany & Australia to expand our commercial reach.
The 14-3-3η JOINTstat test may be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augurex plans to commercialize 14-3-3η tests and reagents in Germany to expand our commercial reach.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.